Agenzia Italiana del Farmaco
Home
AIFA publishes the results of the monitoring related to monoclonal antibodies for the treatment of COVID-19 currently available.
With regard to recent press reports informing about the shortage of azithromycin also due to its excessive and improper use against COVID-19, AIFA points out that neither azithromycin nor any other antibiotics in general are approved or recommended for treating COVID-19.
AIFA makes available, to healthcare professionals, a list of class A and H medicinal products dispensed by the National Health Service, sorted by active ingredient and trade name.
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
Medicines alerts
AIFA Focus
"Do you want to know more about COVID-19 vaccines?"
18 January
09:00 - 19:00
21 January
da definire
25 January
15:30
Competitions
